Non-small Cell Lung Cancer
Conditions
Brief summary
The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy
Interventions
Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
Sponsors
Yongchang Zhang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group Assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Life expectancy exceeds 3 months * The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard.
Exclusion criteria
* small cell lung cancer or small cell lung cancer * Currently involved in interventional clinical research or treatment, or have received other research drugs or used research equipment within 4 weeks prior to the first dose; * Previously received the following treatments: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or synergistically inhibit T cell receptors (eg, CTLA-4, OX-40, CD137);
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Approximately 1 years | To measure the patients's overall response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | Approximately 1 years | Progression free survival |
| OS | Approximately 1 years | Overall survival |
Countries
China
Outcome results
None listed